Sherif El-Refai Assuring The Aspects Of Global Management In Pharmaceutical World

Sherif El-Refai is an ambitious medical professional who recently established his career as a pharmacist in Jersey City. Trained and educated as a pharmacist, Sherif El-Refai has build a background with a graduate degree in business. He recently attended the University of Florida, where he earned a Master of Business Administration that focused on global management, marketing, and competitive strategy.

Besides committing to understand all the aspects of pharmacy, Sherif El-Refai gained experience in developing and submitting Business plans that incorporated pharmacy services into pre existing medical departments. He even completed independent research for the American Journal of Health-System Pharmacists and gained experience to hold a position of pharmacist from 2011-2012.

Since his earning as Doctor of Pharmacy at the University of North Carolina at Chapel hill (UNC-CH) in 2011, Sherif El-Refai gained professional experience in his role as pharmacist in Jersey City. As a UNC_CH student, Sherif El-Refai maintained a dean’s listing distinction, remarkably gaining determination to the National Society of Collegiate Scholars. Additionally he served as a member of the Clinical Discussion Group of Muslim Student Association.

Sherif El-Refai further initiated his UNC-CH research in 2005, where he finished his Bachelor of Science in Pharmaceutical Sciences and then later worked towards a doctorate on the Eshelman School of Pharmacy. During his course he received diverse professional experience serving as a Pharmacy Technician with Eckerd’s Pharmacy from 2006 to 2007.

Sherif El-Refai undertook numerous clerkships during his course of studies, initially completing his Introductory Hospital Experience Rotation at WakeMed Hospitals in Raleigh in 2008 where he subsequently finished his clerkships in the diverse practice areas of hematology/oncology, ambulatory care, inpatient remedy, and ICU trauma.

Sherif El-Refai even contributed to the advancement of his field through numerous research and by writing projects. Collaborating with his pharmacy supervisor, he researched and composed pamphlet for patients titled as “Daily Training Regimen for the Elderly.” he also created brochures on”Medication Therapy Management Services” and gave a presentation discussing the benefits of community partnerships.

Advertisements

Sherif El-Refai – Analyzing Gene Expression To Improve Patient’s Response To Cancer Treatment

With a doctor of pharmacy from the University of North Carolina at Chapel Hill, Sherif El-Refai is now working to earn a PhD in pharmaceutical sciences from the University of Kentucky. As a pharmacist Sherif El-Refai conducts lung cancer research and serves as an oncology pharmacist at the Black Lab, University of Kentucky’s Markey Cancer Center.

Lung cancer is the leading cause of cancer worldwide.The major two forms of lung cancer are nonsmall cell lung cancer (NSCLC=85%) of lung cancer and small-cell lung cancer (SCLC=15%). Despite recent advances in the management of resected lung cancer tumors and more effective treatments in the metastatic setting, the cure rate of lung cancer remains low. Successful molecular testing of lung cancer requires the identification and understanding of events that takes place during the multistep tumorigenic process of lung cancer. As with other solid tumors, lung cancer is the result of the accumulation of genetic and epigenetic alterations over a long course of exposure to a carcinogen.

Discovering new prognostic or predictive biomarkers or developing new detection tools for lung cancer is one of the major areas of transitional cancer research. However, given our current understanding of the multifactorial process of lung carcinogenesis and hetrogeneous nature of the disease, monitoring of one or a few genes is limited. A pangenomic analysis seems more efficient for deciphering the complexity of lung cancer. The prospect of identifying specific events in lung carcinogenesis is significantly brightened by the recent development of high-throughput gene expression analysis.

Sherif El-Refai further tried to understand Gene expression, a biological process at the cellular level involves the conversion of DNA information into molecules such as proteins. The process that allowed the cells to adjust to their surroundings by controlling when and how many proteins are to be produced. The gene expression includes two stages: transcription and translation. During transcription, DNA information is copied to produce messenger RNA, which carries the information to protein-producing ribosomes in the cell. Carrier molecules read this information during the translation stage, and ribosomes use it to form a new protein.

Sherif El-Refai Is Adding significance In The Medical Department

Sherif El-Refai is an accomplished researcher and pharmacist who holds a PhD from the University of North Carolina at Chapel Hill and has even pursued his MBA from the University of Florida. When it comes to the level of proficiency in the field of pharmacy, Sherif El-Refai is committed to understanding all the aspects of the practice and has experience in developing and submitting business plans that incorporate pharmacy services into pre-existing medical departments. He holds certification in pharmacy-based immunization delivery; basic life support; and advanced cardiac life support, anticoagulation, hypertension and lipids, and diabetes.

As a pharmacist in Jersey City, Sherif El-Refai persued a particular interest in the treatment of cancer. A writer and presenter on the topic, Sherif El-Refai hoped to become a leading authority in chemotherapy and its use in complex cases. Further he broadened his experience that included pharmaceutical practice and research, while aiding significant discoveries in the field of pharmacogenomics.

As an active member of the American Pharmacists Association (APhA), Sherif El-Refai holds additional certifications in immunization, anticoagulation, and advanced cardiovascular life support (ACLS). At ACLS classroom program they instructed the students in recognising both respiratory and cardiac arrest, iin additon to symptomatic bradycardia and other peri-arrest conditions. They also addressed early management strategies for these medical emergencies, as well as as airways management, and relevant pharmacology.

Additionally, the course assisted healthcare providers with respect to instances of strokes or acute coronary syndromes. Focusing on the importance of cooperation in cardiovascular life support, the educational program also helped to present strategies for effective communication and leadership while working with a resuscitation team.

Sherif El-Refai Is Associated With The Leading Pharmacy Organizations

Sherif El-Refai is a dedicated academic who has recently earned an MBA from the University of Florida. Here, he focused on marketing, competitive strategy, and global management. While managing his studies, he also handled the role of the Case Competition Club, which he revived to offer students an opportunity to apply problem-solving skills to real business cases.

Prior to earning an MBA, Sherif El-Refai earned a doctor of pharmacy and a Bachelor of Science in pharmaceutical sciences from the University of North Carolina. (UNC) at Chapel Hill. He gained experience in the pharmaceutical field by doing comprehensive research and service work with organizations such as the Institute for Pharmacogenomics & Individualized Therapy, and the Center for Pharmacogenomics’ Department of Pharmacotherapy and Translational Research.

While working with the UNC Memorial Hospitals, he completed a comprehensive analysis if a specific treatment regimen for the company via Oncology, presented his findings to the company’s divisional board of directors, and induced the company to implement his recommended changes to the regimen.

Being an active member of the pharmaceutical industry, Sherif El-Refai has published research and performed presentations on a wide range of subjects, including Hypercalcemia of Malignancy. Besides being a renowned pharmacist,, he is also associated with the leading pharmacy organizations which adds five star to his profile. He also maintains memberships with the American Pharmacists Association, the American Society of Health-System Pharmacists, and the North Carolina Association of Pharmacists.

The Cancer Screening Program at the Markey Cancer Center

Markey Cancer Center pic
Markey Cancer Center
Image: ukhealthcare.uky.edu

Sherif El-Refai is a PhD student at the University of Kentucky where he studies pharmaceutical sciences with a focus on clinical and experimental therapeutics. An experienced clinical researcher, Sherif El-Refai currently serves as an oncology pharmacist at the University of Kentucky’s Markey Cancer Center.

The Markey Cancer Center is a healthcare and research institution that has been providing cancer treatment for more than two decades. The center, which is in Lexington, Kentucky, offers innovative technology and high-quality, individualized patient care provided by a team of leading cancer specialists. In addition, the center operates wellness programs such as the Cancer Screening Program.

The Cancer Screening Program operates in partnership with education programs, research groups, and healthcare providers to offer comprehensive cancer prevention and screening services. Screenings, which are free for individuals who meet eligibility requirements, are available for lung, ovarian, prostate, skin, breast, cervical, and colorectal cancers. In addition, the American Cancer Society collaborates with the Markey Cancer Center to provide recommendations related to screenings. For more information on the program, visit www.ukhealthcare.edu/markeypatients-families/cancer-screening/.

University of Kentucky Cancer Screening Helps Prevent Lung Cancer

Lung Cancer pic
Lung Cancer
Image: ukhealthcare.uky.edu

A pharmaceutical sciences PhD student at the University of Kentucky (UK), Sherif El-Refai is a translational researcher focused on immuno-oncology in lung cancer at the university’s Markey Cancer Center. To compliment his oncology pharmaceutical practice, Sherif El-Refai conducts research on lung cancer treatment, prevention, and diagnosis.

Lung cancer is the leading cause of cancer-related deaths in the United States. Every year, it kills more people than colorectal, prostate, and breast cancer combined. The best way to prevent lung cancer is to stop smoking. For those who smoke regularly, lung cancer screening is recommended to detect the cancer early and to reduce the risk of lung cancer death.

UK’s lung cancer screening program was designed for persons at risk of developing lung cancer. These include seniors older than 55, people who smoke or have recently quit smoking, and people who have been smoking a pack or more fa day or over 30 years. The screening uses a computed tomography scan to reveal suspicious cancerous spots in the lungs. Patients diagnosed with the cancer are referred to the university’s Markey Cancer Center, where a multidisciplinary team of medical care givers will commence treatment.

Research Indicates Histone Protein Inhibition as Cancer Treatment

Sherif El-Refai

Sherif El-Refai focuses his work on experimental and clinical interventions. Sherif El-Refai currently works within the University of Kentucky’s Black lab, where researchers use gene expression to develop targeted cancer treatments.

In March 2017, researchers at Rockefeller University announced the development of an intervention that may reduce tumor growth by regulating gene expression. The research centers on proteins known as histones, changes to which may activate or deactivate a gene. Reader proteins within the cell then bind to the altered histone and facilitate activity of the gene.

Cancer researchers have already identified a type of reader protein known as the BET protein, which can inhibit tumor growth. The new discovery from the research team at Rockefeller University involves a type of protein that has similar potential to the BET protein but that shares a particular feature known as a YEATS domain. Like the BET protein, a protein with the YEATS domain binds to histones affected by a chemical mark known as an acetyl group.

Although the relevance of this particular functionality is as yet unknown, researchers do know that proteins with the YEATS domain may fuse with the MLL protein in certain patients with leukemia. Researchers tested this function by deleting a YEATS domain protein known as ENL from leukemia cells in mice, who had a significantly improved prognosis following the transplant of ENL-depleted proteins.

Researchers are now working on developing combination therapies that combine YEATS domain blockage with existing drugs that work as bromodomain inhibitors. The hope is to further explore the potential of YEATS domain blockers not only in leukemia but also in cancers of other types.